All In MedTech

Device Trial Radar · NCT07158177

Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity

Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity. Study of Two Different Material of Intra Ocular Multifocal Lenses Aiming to Compare the Effect on Contrast Sensitivity.

Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 1, 2025

Primary completion

Oct 15, 2026

Study completion Oct 15, 2026

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alcon Research; URC-CIC Paris Descartes Necker Cochin
First posted
Sep 5, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Retrospective, comparative, interventional, randomized, single-center study, contralateral (the patient's 2 eyes will be implanted: 1 CPO and the other APO) Patients presenting for cataract surgery with a request for presbyopia correction and managed as part of routine clinical practice. The main aim of the study is to demonstrate that contrast sensitivity is better with the Clareon PanOptix (CPO) intraocular lens (IOL) compared with the AcrySof PanOptix (APO) IOL 3 months after implantation.

Conditions

  • Cataract and IOL Surgery

Interventions

  • Acrysof™ PanOptix™ toric or not, trifocal IOL CE marked, Alcon company.Device

    both of the patient's eyes will be implanted: 1 CPO and the other APO

  • Clareon PanoptixDevice

    both of the patient's eyes will be implanted: 1 CPO and the other APO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Contrast sensitivity measured at 3 monthsTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Assistance Publique - Hôpitaux de Paris, Ophtalomopôle - Hôpital COCHIN

    Paris, Île-de-France Region, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.